ACB $6.530 (-5.22%)

ACNNF $0.112 (0%)

AERO $3.135 (-3.83%)

AGEEF $0.063 (-3.09%)

ALEAF $0.389 (-0.23%)

AMMJ $0.073 (-2.28%)

APHA $4.680 (0.43%)

ARNA $71.250 (0.95%)

ATT:CNX $0.080 (0%)

ATTBF $0.007 (2.33%)

AUSA:CNX $0.155 (6.9%)

AUSAF $0.123 (0%)

AVXL $4.250 (1.43%)

BAMM:CNX $0.390 (2.63%)

BBM:CNX $0.055 (10%)

BBRRF $0.040 (4.58%)

BE:CNX $0.005 (0%)

BIO:CNX $0.070 (16.67%)

BLEVF $0.004 (26.67%)

BLIS:CNX $0.315 (0%)

BLO:CNX $0.430 (-8.51%)

BLOZF $0.330 (-5.71%)

BUDZ $0.200 (-4.76%)

BXNG $0.440 (0%)

CADMF $0.633 (-4.99%)

CALI:CNX $0.070 (0%)

CANN $0.318 (5.83%)

CARA $14.530 (-1.62%)

CBII:CNX $0.190 (2.7%)

CBIIF $0.144 (1.74%)

CBWTF $0.110 (-6.38%)

CGC $16.360 (-0.24%)

CGRW $0.084 (9.09%)

CHOO:CNX $0.090 (-5.26%)

CHOOF $0.067 (-5.91%)

CNBX $0.175 (1.72%)

CNGGF $0.270 (0%)

CODI $17.700 (0.45%)

CPMD $0.650 (1.58%)

CRBP $1.900 (-3.06%)

CRON $5.290 (0.95%)

CROP:CNX $0.015 (0%)

CRTPF $2.300 (-9.95%)

CRXPF $0.050 (46.55%)

CSI:CNX $0.920 (0%)

CURR $1.440 (-3.36%)

CVSI $0.530 (3.33%)

DIGP $0.026 (1.37%)

DXBRF $0.140 (0%)

EAPH $0.001 (0%)

EAT:CNX $0.015 (50%)

EEVVF $0.054 (2.45%)

EMHTF $0.151 (-5.63%)

EPWCF $0.034 (-4.72%)

EVIO $0.017 (12.67%)

FFRMF $0.025 (0.2%)

FFT:CNX $0.040 (0%)

FNNZF $0.053 (0%)

GGTTF $0.060 (-17.15%)

GLDFF $0.017 (-4.55%)

GLH:CNX $0.020 (0%)

GNBT $0.247 (5.11%)

GRIN:CNX $0.110 (4.76%)

GRWG $15.970 (1.62%)

GSTR:CNX $0.050 (-9.09%)

GTBIF $14.100 (-0.35%)

GTII:CNX $18.620 (-0.05%)

GWPH $100.180 (-1.79%)

HEXO $0.774 (1.78%)

HLSPY $0.385 (0%)

HMLSF $4.655 (-1.58%)

HMPPF $0.498 (0%)

HRVOF $0.050 (-10.07%)

HSTRF $0.084 (5.41%)

HUGE:CNX $3.640 (-2.93%)

IAN:CNX $0.090 (0%)

IGC $1.190 (0%)

IGXT $0.150 (-1.24%)

IIPR $124.790 (-1.1%)

IMLFF $3.678 (-1.14%)

INQD $0.003 (0%)

IONC:CNX $0.015 (0%)

IONKF $0.015 (-28.57%)

ISOL:CNX $0.035 (16.67%)

ISOLF $0.030 (34.53%)

ITHUF $0.072 (-5.3%)

IVITF $0.007 (84.21%)

JWCAF $0.004 (0%)

KBEV:CNX $0.060 (0%)

KBEVF $0.041 (-7.22%)

KHRNF $0.359 (-2.93%)

KSHB $0.470 (1.73%)

LHS:CNX $0.510 (-1.92%)

LHSIF $0.396 (0.76%)

LOVE:CNX $0.090 (0%)

LXRP $0.265 (-2.48%)

LXX:CNX $0.345 (-1.43%)

MCIG $0.028 (0%)

MEDIF $0.676 (-2.55%)

MGWFF $0.051 (-9.94%)

MICWF $0.079 (0%)

MJ:CNX $0.035 (0%)

MJNA $0.014 (0.36%)

MNTR $0.080 (-2.38%)

MRRCF $0.004 (5.88%)

MWM:CNX $0.095 (0%)

MYM:CNX $0.055 (-8.33%)

MYMMF $0.041 (-12.21%)

NCNNF $0.140 (6.87%)

NDVAF $0.186 (-5.11%)

NGW:CNX $0.215 (-2.27%)

NRXCF $0.093 (-8.79%)

NSPDF $0.049 (-3.07%)

NTEC $0.283 (0.86%)

NVTQF $0.451 (0%)

NWKRF $0.424 (0%)

NXGWF $0.165 (-0.93%)

NXTTF $0.187 (-0.21%)

OH:CNX $5.330 (0%)

ORHOF $4.050 (0%)

OWCP $0.009 (-0.56%)

PHCG $0.500 (0%)

PHVAF $0.038 (-5.71%)

PILL:CNX $0.650 (0%)

PKG:CNX $0.075 (-6.25%)

PLPRF $0.460 (-2.56%)

PLUS:CNX $0.610 (-1.61%)

PMCB $0.011 (-7.89%)

PNPL $0.200 (0%)

POTN $0.014 (5.19%)

PRCNF $0.008 (-15.79%)

PTNYF $0.055 (-3.74%)

QCA:CNX $0.125 (4.17%)

RDDTF $0.082 (-11.54%)

RLLVF $0.041 (-30.51%)

RMHB $0.053 (1.92%)

RQB:CNX $0.005 (0%)

RQHTF $0.181 (1.68%)

RVVQF $0.007 (-12.5%)

SLNG:CNX $0.135 (3.85%)

SMG $149.130 (-3.63%)

SNN:CNX $0.155 (0%)

SNNVF $0.115 (15%)

SOL:CNX $1.050 (2.94%)

SOLCF $0.747 (-1.76%)

SPLIF $0.012 (14.5%)

SPRWF $0.115 (-3.69%)

SRNA $0.023 (-0.44%)

STEM:CNX $0.340 (11.48%)

STMH $0.260 (8.33%)

SUN:CNX $0.150 (-14.29%)

TBPMF $0.131 (0%)

TCAN:CNX $0.930 (-1.06%)

TCNAF $0.708 (0%)

TER:CNX $6.000 (0%)

TGEN $0.752 (-4.86%)

TGIF:CNX $0.060 (0%)

TGIFF $0.045 (-3.62%)

THC:CNX $0.140 (-3.45%)

THCBF $0.106 (-3.64%)

TLRY $5.340 (-1.66%)

TOKI:CNX $0.030 (0%)

TRLFF $0.027 (8%)

TRSSF $4.530 (-0.22%)

TRTC $0.073 (2.16%)

TURV $0.117 (-10.28%)

VBIO $0.160 (-20%)

VIDA:CNX $0.055 (0%)

VIN:CNX $0.015 (0%)

VPRB $0.023 (4.55%)

VRNDF $0.443 (0%)

VRT:CNX $0.150 (0%)

VRTHF $0.115 (0%)

VVCIF $0.152 (0.76%)

WAYL:CNX $0.740 (0%)

WDDMF $0.243 (-7.72%)

WLDFF $0.120 (0.5%)

XXII $0.570 (-2.11%)

ZDPY $0.225 (-6.25%)

ZYNE $3.700 (-2.63%)

Technical420 Site Search

Returned 7 result(s).

Cardiol Therapeutics Initiates Health Canada Approved Phase 1 Clinical Study of CardiolRx(TM)

Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the development of pharmaceutical cannabidiol formulations for the treatment of cardiovascular diseases, including heart failure and acute myocarditis, is pleased to announce the initiation of its Health Canada approved Phase 1 clinical study of CardiolRx™. CardiolRx…

Cardiol Therapeutics Could Be Sitting On A Breakthrough Therapy To Treat A Major Covid-19 Related Condition

Following the COVID pandemic, the level of safety in college sports has come under heavy scrutiny and has become one of the most highly talked about subjects. One of the most significant health concerns that is associated with college athletes in the COVID era is Myocarditis, which is the inflammation…

GW Pharmaceuticals plc Reports Second Quarter 2020 Financial Results and Operational Progress

GW Pharmaceuticals plc (Nasdaq: GWPH), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced financial results and operating progress for the second quarter ended June 30, 2020. “We were pleased with the strength of U.S. Epidiolex sales in the second quarter in spite of…

Cardiol Therapeutics Is Developing Innovative Cannabidiol Products To Treat Major Indications

2020 has been a challenging year for the global economy and almost all industries have been negatively impacted by COVID-19 as the virus has forced numerous businesses to shut down. There are a number of companies that are working around the clock to develop a treatment for this highly contagious…

Cardiol Therapeutics To Benefit On The Rescheduling Of GW Pharma’s Epidiolex By The DEA

Earlier this year, the Drug Enforcement Administration (DEA) announced a significant development for patients who need to access Epidiolex, the only federally approved drug derived from cannabis. Epidiolex is manufactured and sold by GW Pharmaceuticals (GWPH) and is no longer considered to be a controlled substance under the Controlled Substances…

Cardiol Therapeutics Is Leveraging Cutting Edge Technology and World Class Partnerships To Disrupt The Multi-Billion Dollar CBD Market

As the summer season comes to a close, the cannabis sector is trending higher and this is something that we are watching. During the last quarter, the sector had been under pressure with several leading companies impacted by the decline. Although the weakness over the summer was concerning, we believe…

Cardiol Therapeutics’ Pharmaceutical Partner Noramco Presents at U.S. FDA Public Hearing on CBD

Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a leader in the research and commercial development of pharmaceutical cannabidiol (CBD) and targeted therapies for inflammatory diseases, announces that Noramco, Inc. (Noramco) of Wilmington, Delaware, Cardiol's pharmaceutical partner and manufacturer of its pure pharmaceutical CBD, was selected to…

Search Again